EED226是一种强效的多梳抑制复合物2（PRC2）抑制剂，IC50值为22.3nM。
Cas No.:2083627-02-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
EED226 is a potent inhibitor of Polycomb repressive complex 2 (PRC2) with an IC50 value of 22.3nM [1]. EED226 binds to the H3K27Me3 binding pocket of EED through a allosteric mechanism, thereby inhibiting the function of PRC2. It effectively suppresses the level of H3K27Me3 in the cell and regulates the expression of target genes. [2]. EED226 has been widely used in cell and animal models to inhibit tumor progression[3].
In vitro, EED226 treatment for 5 days significantly inhibited the proliferation of NGP and IMR32 cells, with IC50 values of 2.64μM and 2.05μM, respectively[4]. EED226 treatment at 5μM for 48 hours significantly enhanced the proliferation of female germline stem cells (FGSCs), promoted the expression of OCT4, and inhibited the expression of P53 and P63[5].
In vivo, EED226 treatment via daily intragastric administration (40mg/kg) twice for 2 days improved renal function and alleviated renal injury in the mouse model of acute kidney injury (AKI) induced by cisplatin[6]. Oral administration of EED226 twice daily (40mg/kg) for 32 days can inhibit tumor growth in the Karpas422-xenograft mouse models[7]. Oral administration of EED226 twice daily (40mg/kg) for 30 days effectively alleviated the symptoms of experimental autoimmune encephalomyelitis (EAE) in mice and improved inflammatory infiltration[8].
References:
[1] Cook N, Chen J, Zhou J, et al. Embryonic ectoderm development (EED) as a novel target for cancer treatment[J]. Current topics in medicinal chemistry, 2021, 21(31): 2771-2777.
[2] Liu K L, Zhu K, Zhang H. An overview of the development of EED inhibitors to disable the PRC2 function[J]. RSC Medicinal Chemistry, 2022, 13(1): 39-53.
[3] Atadja P W. Abstract IA19: Targeting the PRC2 complex through EED for anti-cancer therapy[J]. Cancer Research, 2017, 77(22_Supplement): IA19-IA19.
[4] Shaliman D, Takenobu H, Sugino R P, et al. The PRC2 molecule EED is a target of epigenetic therapy for neuroblastoma[J]. European Journal of Cell Biology, 2022, 101(3): 151238.
[5] Wang J, Fang J, Feng M, et al. Inhibition of EED activity enhances cell survival of female germline stem cell and improves the oocytes production during oogenesis in vitro[J]. Open Biology, 2023, 13(1).
[6] Yu C, Li T, Li J, et al. Inhibition of polycomb repressive complex 2 by targeting EED protects against cisplatin‐induced acute kidney injury[J]. Journal of Cellular and Molecular Medicine, 2022, 26(14): 4061-4075.
[7] Qi W, Zhao K, Gu J, et al. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED[J]. Nature chemical biology, 2017, 13(4): 381-388.
[8] Hong W, Ma H, Li Z, et al. Inhibition of EED-mediated histone methylation alleviates neuroinflammation by suppressing WNT-mediated dendritic cell migration[J]. Journal of Neuroinflammation, 2025, 22(1): 97.
EED226是一种强效的多梳抑制复合物2（PRC2）抑制剂，IC50值为22.3nM[1]。EED226通过变构机制结合到EED的H3K27Me3结合口袋，从而抑制PRC2的功能，能有效降低细胞中H3K27Me3的水平，并调控靶基因的表达[2]。EED226已被广泛用于细胞和动物模型中抑制肿瘤进展[3]。
在体外，EED226处理5天显著抑制了NGP和IMR32细胞的增殖，IC50值分别为2.64μM和2.05μM[4]。使用5μM的EED226处理48小时，显著增强了雌性生殖干细胞（FGSCs）的增殖，促进了OCT4的表达，并抑制了P53和P63的表达[5]。
在体内，每日两次灌胃给予EED226（40mg/kg），连续2天，改善了顺铂诱导的急性肾损伤（AKI）小鼠模型中的肾功能，并减轻了肾损伤[6]。每日两次口服EED226（40mg/kg），连续32天，可抑制Karpas422细胞异种移植小鼠模型中的肿瘤生长[7]。每日两次口服EED226（40mg/kg），连续30天，有效减轻了小鼠实验性自身免疫性脑脊髓炎（EAE）的症状，并改善了炎症浸润[8]。
| Cell experiment [1]: | |
Cell lines | IMR32 cells |
Preparation Method | IMR32 cells were cultured in RPMI1640 medium supplemented with 10% fetal bovine serum (FBS) and 50µg/ml penicillin in a humidified atmosphere containing 5% CO2 at 37°C. IMR32 cells were seeded in 96-well plates at a density of 103 cells/well. Cells were treated with different concentrations of EED226 (0, 1, 2, 5, and 10μM) for 5 days. Then, the cell viability was analyzed. |
Reaction Conditions | 0, 1, 2, 5, and 10μM; 5 days |
Applications | EED226 treatment significantly reduced the cell viability of IMR32 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | C57BL/6J mice |
Preparation Method | C57BL/6J mice (20-23g) were kept in temperature-controlled (21°C-25°C) and humidity-maintained (40%-70%) rooms with a 12-h light/dark cycle. Water and food were provided freely. To establish a mouse model of cisplatin-induced AKI, the mice were injected intraperitoneally with cisplatin (25mg/kg) in saline. EED226 (40mg/kg) dissolved in corn oil and DMSO was administered intragastrically immediately after cisplatin injection, and then administered twice a day for 2 days. The control group received the same amount of vehicle. Mice were euthanized and kidney samples were collected for histological examination. |
Dosage form | 40mg/kg; twice a day for 2 days; p.o. |
Applications | EED226 treatment improved renal function and attenuated renal tubular cell injury in the murine model of cisplatin-induced AKI. |
References: | |
| Cas No. | 2083627-02-3 | SDF | |
| Canonical SMILES | O=S(C1=CC=C(C2=CN=C(NCC3=CC=CO3)N4C2=NN=C4)C=C1)(C)=O | ||
| 分子式 | C17H15N5O3S | 分子量 | 369.4 |
| 溶解度 | DMSO : ≥ 29 mg/mL (78.51 mM);Water : < 0.1 mg/mL (insoluble) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7071 mL | 13.5355 mL | 27.0709 mL |
| 5 mM | 541.4 μL | 2.7071 mL | 5.4142 mL |
| 10 mM | 270.7 μL | 1.3535 mL | 2.7071 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet